Last reviewed · How we verify
CC100
At a glance
| Generic name | CC100 |
|---|---|
| Also known as | synthetic caffeic acid phenethylester |
| Sponsor | Chemigen, LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- One-shot Ovarian Stimulation Protocol (One-shot) (NA)
- Comparison of Sternal Wound Infiltration With Liposomal Bupivacaine v. Bupivacaine Hydrochloride (PHASE3)
- Progestin-induced Endometrial Shedding in PCOS (The PIES in PCOS Study) (NA)
- "Stair Step Study" (PHASE4)
- CC100: Phase 1 Multiple-Dose Safety and Tolerability in Subjects With ALS (PHASE1)
- CC100: Safety and Tolerability of Single Doses (PHASE1)
- Coenzyme Q10 and Clomiphene Citrate (CC) for Ovulation Induction in Polycystic Ovary Syndrome (NA)
- Efficacy of Ketamine-Propofol for Short Surgical Procedures (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CC100 CI brief — competitive landscape report
- CC100 updates RSS · CI watch RSS
- Chemigen, LLC portfolio CI